Maria Pantelidou

Guy's and St Thomas' NHS Foundation Trust

Papers

1

Total Citations

62

H-Index

1

About

Dr. Maria Pantelidou is a leading urologic oncologist whose research focuses on optimizing treatment strategies for renal cell carcinoma (RCC), particularly through minimally invasive techniques. Her most cited work, a 2016 retrospective analysis comparing percutaneous radiofrequency ablation (RFA) with robotic-assisted partial nephrectomy (RPN) for small renal tumors, has garnered 62 citations and provides critical comparative data on oncologic outcomes for T1 stage RCC. This study, conducted at a high-volume tertiary centre, directly informs clinical decision-making for patients and surgeons weighing the benefits of thermal ablation versus robotic surgery. Beyond this landmark paper, Dr. Pantelidou’s broader contributions include advancing the evidence base for nephron-sparing approaches, refining patient selection criteria, and evaluating long-term survival outcomes. Her work has been instrumental in demonstrating that both RFA and RPN offer effective, minimally invasive options for small renal masses, helping to reduce overtreatment while preserving renal function. With a career dedicated to bridging surgical innovation and evidence-based practice, Dr. Pantelidou continues to shape the landscape of urologic oncology through rigorous clinical research and collaborative, patient-centered care.

Research Focus

Key Achievements

1
H-Index
1
Papers
62
Total Citations
62
Avg Citations/Paper
🏆 Most Cited Paper
Percutaneous Radiofrequency Ablation Versus Robotic-Assisted Partial Nephrectomy for the Treatment of Small Renal Cell Carcinoma
62 citations · 2016
📈 Most Prolific Year: 2016 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Guy's and St Thomas' NHS Foundation Trust

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago